Krystal Biotech awarded director Catherine Mazzacco 1,658 derivative securities through two transactions dated 2026-09-14, with a stated price of $0 per share. Transaction code A identifies the entries as awards or grants, giving investors a precise record of the insider transaction and its reported pricing.
Key Highlights
- The transactions used SEC transaction code A.
- The 1,658 derivative securities were awarded across two separate transactions.
- The reported transaction price was $0 per share.
Krystal Biotech, Inc. (NASDAQ: KRYS) awarded director Catherine Mazzacco 1,658 derivative securities on 14 September 2026. The filing identifies the securities as derivative securities.
Two Transactions Recorded Under Code A
The award was split across two separate transactions, both using transaction code A. The filing states that both transactions used SEC transaction code A. The reported consideration was $0 per share. Catherine Mazzacco is identified as a director of Krystal Biotech, Inc. and the securities involved are derivative securities.
FAQs
Q: What did Catherine Mazzacco receive from Krystal Biotech?
A: Catherine Mazzacco received 1,658 derivative securities from Krystal Biotech across two separate transactions dated 14 September 2026. The filing identifies her as a director.
Q: What was the price of the Krystal Biotech insider award?
A: The reported price was $0 per share for the two transactions. The filing states that the derivative securities were awarded to Catherine Mazzacco, a Krystal Biotech director.
Q: What does transaction code A mean in this Krystal Biotech transaction?
A: Transaction code A denotes an award, grant, or other acquisition from the company.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.